139 related articles for article (PubMed ID: 11426466)
1. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study.
Kang WK; Park C; Yoon HL; Kim WS; Yoon SS; Lee MH; Park K; Kim K; Jeong HS; Kim JA; Nam SJ; Yang JH; Son YI; Baek CH; Han J; Ree HJ; Lee ES; Kim SH; Kim DW; Ahn YC; Huh SJ; Choe YH; Lee JH; Park MH; Kong GS; Park EY; Kang YK; Bang YJ; Paik NS; Lee SN; Kim SH; Kim S; Robbins PD; Tahara H; Lotze MT; Park CH
Hum Gene Ther; 2001 Apr; 12(6):671-84. PubMed ID: 11426466
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study.
Sun Y; Jurgovsky K; Möller P; Alijagic S; Dorbic T; Georgieva J; Wittig B; Schadendorf D
Gene Ther; 1998 Apr; 5(4):481-90. PubMed ID: 9614572
[TBL] [Abstract][Full Text] [Related]
3. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector.
Tahara H; Zitvogel L; Storkus WJ; Zeh HJ; McKinney TG; Schreiber RD; Gubler U; Robbins PD; Lotze MT
J Immunol; 1995 Jun; 154(12):6466-74. PubMed ID: 7759882
[TBL] [Abstract][Full Text] [Related]
4. Retroviral-mediated transfer of genes encoding interleukin-2 and interleukin-12 into fibroblasts increases host antitumor responsiveness.
Govaerts AS; Guillaume T; André M; Bayat B; Feyens AM; Hawley TS; Fong AZ; Hawley RG; Symann M
Cancer Gene Ther; 1999; 6(5):447-55. PubMed ID: 10505855
[TBL] [Abstract][Full Text] [Related]
5. Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity.
Fakhrai H; Shawler DL; Gjerset R; Naviaux RK; Koziol J; Royston I; Sobol RE
Hum Gene Ther; 1995 May; 6(5):591-601. PubMed ID: 7578396
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma.
Triozzi PL; Strong TV; Bucy RP; Allen KO; Carlisle RR; Moore SE; Lobuglio AF; Conry RM
Hum Gene Ther; 2005 Jan; 16(1):91-100. PubMed ID: 15703492
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of retroviral vector-mediated interferon (IFN)-gamma gene transfer into autologous tumor cells in patients with metastatic melanoma.
Nemunaitis J; Bohart C; Fong T; Meyer W; Edelman G; Paulson RS; Orr D; Jain V; O'Brien J; Kuhn J; Kowal KJ; Burkeholder S; Bruce J; Ognoskie N; Wynne D; Martineau D; Ando D
Cancer Gene Ther; 1998; 5(5):292-300. PubMed ID: 9824048
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model.
Elzaouk L; Moelling K; Pavlovic J
Exp Dermatol; 2006 Nov; 15(11):865-74. PubMed ID: 17002683
[TBL] [Abstract][Full Text] [Related]
9. Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man.
Kasid A; Morecki S; Aebersold P; Cornetta K; Culver K; Freeman S; Director E; Lotze MT; Blaese RM; Anderson WF
Proc Natl Acad Sci U S A; 1990 Jan; 87(1):473-7. PubMed ID: 2404283
[TBL] [Abstract][Full Text] [Related]
10. Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer.
Elder EM; Lotze MT; Whiteside TL
Hum Gene Ther; 1996 Mar; 7(4):479-87. PubMed ID: 8800742
[TBL] [Abstract][Full Text] [Related]
11. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial.
Stewart AK; Lassam NJ; Quirt IC; Bailey DJ; Rotstein LE; Krajden M; Dessureault S; Gallinger S; Cappe D; Wan Y; Addison CL; Moen RC; Gauldie J; Graham FL
Gene Ther; 1999 Mar; 6(3):350-63. PubMed ID: 10435085
[TBL] [Abstract][Full Text] [Related]
12. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP
Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224
[TBL] [Abstract][Full Text] [Related]
13. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
Yang SC; Grimm EA; Parkinson DR; Carinhas J; Fry KD; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub LB; Hong WK; Roth JA
Cancer Res; 1991 Jul; 51(14):3669-76. PubMed ID: 1648441
[TBL] [Abstract][Full Text] [Related]
14. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.
Tahara H; Zeh HJ; Storkus WJ; Pappo I; Watkins SC; Gubler U; Wolf SF; Robbins PD; Lotze MT
Cancer Res; 1994 Jan; 54(1):182-9. PubMed ID: 7903204
[TBL] [Abstract][Full Text] [Related]
15. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent.
Liu K; Rosenberg SA
J Immunother; 2003; 26(3):190-201. PubMed ID: 12806273
[TBL] [Abstract][Full Text] [Related]
17. Treatment of murine hepatocellular carcinoma using genetically modified cells to express interleukin-12.
Peron JM; Couderc B; Rochaix P; Douin-Echinard V; Asnacios A; Souque A; Voigt JJ; Buscail L; Vinel JP; Favre G
J Gastroenterol Hepatol; 2004 Apr; 19(4):388-96. PubMed ID: 15012775
[TBL] [Abstract][Full Text] [Related]
18. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma.
Zhang L; Morgan RA; Beane JD; Zheng Z; Dudley ME; Kassim SH; Nahvi AV; Ngo LT; Sherry RM; Phan GQ; Hughes MS; Kammula US; Feldman SA; Toomey MA; Kerkar SP; Restifo NP; Yang JC; Rosenberg SA
Clin Cancer Res; 2015 May; 21(10):2278-88. PubMed ID: 25695689
[TBL] [Abstract][Full Text] [Related]
19. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma.
Tanaka M; Saijo Y; Sato G; Suzuki T; Tazawa R; Satoh K; Nukiwa T
Cancer Gene Ther; 2000 Nov; 7(11):1481-90. PubMed ID: 11129290
[TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha and interleukin-12 gene therapy of cancer: interferon-alpha induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing.
Eguchi J; Hiroishi K; Ishii S; Mitamura K
Cancer Immunol Immunother; 2003 Jun; 52(6):378-86. PubMed ID: 12739068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
